CoChat

Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective

Open access
Derry, Paul J., Hegde, Muralidhar L., Jackson, George R., Kayed, Rakez, Tour, James M., Tsai, Ah-Lim, Kent, Thomas A. · 2020 · Progress in Neurobiology
Cited by 140

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

Abstract

The complexity of Alzheimer’s disease (AD) complicates the search for effective treatments. While the key roles of pathologically modified proteins has occupied a central role in hypotheses of the pathophysiology, less attention has been paid to the potential role for transition metals overload, subsequent oxidative stress, and tissue injury. The association of transition metals, the major focus heretofore iron and amyloid, the same can now be said for the likely pathogenic microtubular associated tau (MAPT). This review discusses the interplay between iron, pathologically modified tau and oxidative stress, and connects many related discoveries. Basic principles of the transition to pathological MAPT are discussed. Iron, its homeostatic mechanisms, the recently described phenomenon of ferroptosis and purported, although still controversial roles in AD are reviewed as well as considerations to overcome existing hurdles of iron-targeted therapeutic avenues that have been attempted in AD. We summarize the involvement of multiple pathological pathways at different disease stages of disease progression that supports the potential for a combinatorial treatment strategy targeting multiple factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pneurobio.2019.101716

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 90 references

Research works printed but not linked: 164

  1. Acosta-Cabronero, 2016, In vivo MRI mapping of brain iron deposition across the adult lifespan, J. Neurosci., 36, 364, 10.1523/JNEUROSCI.1907-15.2016 · DOI · Paper page
  2. Aguirre, 2012, The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1, Biometals, 25, 795, 10.1007/s10534-012-9525-y · DOI
  3. Ahmadi, 2017, Electrochemical studies of tau protein-iron interactions—potential implications for Alzheimer’s disease, Electrochim. Acta, 236, 384, 10.1016/j.electacta.2017.03.175 · DOI
  4. Alim, 2019, Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke, Cell, 177, 10.1016/j.cell.2019.03.032 · DOI · Paper page
  5. Alzheimer’s, 2012, 2012 Alzheimer’s disease facts and figures, Alzheimers Dement., 8, 131, 10.1016/j.jalz.2012.02.001 · DOI · Paper page
  6. Arif, 2014, Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of tau, J. Biol. Chem., 289, 27677, 10.1074/jbc.M114.565358 · DOI
  7. Ayala, 2014, Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal, Oxid. Med. Cell. Longev., 2014, 360438, 10.1155/2014/360438 · DOI · Paper page
  8. Ayton, 2018, Evidence that iron accelerates Alzheimer’s pathology: a CSF biomarker study, J. Neurol. Neurosurg. Psychiatry, 89, 456, 10.1136/jnnp-2017-316551 · DOI · Paper page
  9. Ayton, 2017, Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline, Brain, 140, 2112, 10.1093/brain/awx137 · DOI · Paper page
  10. Bader, 2011, Single particle analysis of tau oligomer formation induced by metal ions and organic solvents, Biochem. Biophys. Res. Commun., 411, 190, 10.1016/j.bbrc.2011.06.135 · DOI
  11. Ballard, 2016, Dementia in Down’s syndrome, Lancet Neurol., 15, 622, 10.1016/S1474-4422(16)00063-6 · DOI · Paper page
  12. Bareggi, 2012, Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders, CNS Neurosci. Ther., 18, 41, 10.1111/j.1755-5949.2010.00231.x · DOI · Paper page
  13. Bautista, 2016, Iron-induced oxidative stress activates AKT and ERK1/2 and decreases Dyrk1B and PRMT1 in neuroblastoma SH-SY5Y cells, J. Trace Elem. Med. Biol., 34, 62, 10.1016/j.jtemb.2015.11.005 · DOI
  14. Belaidi, 2016, Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease: targets for therapeutics, J. Neurochem., 139, 179, 10.1111/jnc.13425 · DOI · Paper page
  15. Berlett, 1997, Protein oxidation in aging, disease, and oxidative stress, J. Biol. Chem., 272, 20313, 10.1074/jbc.272.33.20313 · DOI · Paper page
  16. Bertrand, 2013, Non-invasive, in vivo monitoring of neuronal transport impairment in a mouse model of tauopathy using MEMRI, Neuroimage, 64, 693, 10.1016/j.neuroimage.2012.08.065 · DOI · Paper page
  17. Betrie, 2017, Evidences of a cardiovascular function for microtubule-associated protein tau, J. Alzheimer’s Dis., 56, 849, 10.3233/JAD-161093 · DOI
  18. Bhandary, 2012, An involvement of oxidative stress in endoplasmic reticulum stress and its associated diseases, Int. J. Mol. Sci., 14, 434, 10.3390/ijms14010434 · DOI · Paper page
  19. Billingsley, 1997, Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration, Biochem. J., 323, 577, 10.1042/bj3230577 · DOI · Paper page
  20. Bolognin, 2011, Aluminum, copper, iron and zinc differentially alter amyloid-Abeta(1-42) aggregation and toxicity, Int. J. Biochem. Cell Biol., 43, 877, 10.1016/j.biocel.2011.02.009 · DOI · Paper page
  21. Buée, 2000, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Brain Res. Rev., 33, 95, 10.1016/S0165-0173(00)00019-9 · DOI · Paper page
  22. Cardoso, 2017, Glutathione peroxidase 4: a new player in neurodegeneration?, Mol. Psychiatry, 22, 328, 10.1038/mp.2016.196 · DOI · Paper page
  23. Cascio, 2018, Azure C targets and modulates toxic tau oligomers, ACS Chem. Neurosci., 9, 1317, 10.1021/acschemneuro.7b00501 · DOI · Paper page
  24. Cecchi, 1999, Gluthatione level is altered in lymphoblasts from patients with familial Alzheimer’s disease, Neurosci. Lett., 275, 152, 10.1016/S0304-3940(99)00751-X · DOI · Paper page
  25. Celardo, 2011, Pharmacological potential of cerium oxide nanoparticles, Nanoscale, 3, 1411, 10.1039/c0nr00875c · DOI · Paper page
  26. Chen, 2008, I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A, J. Biol. Chem., 283, 10513, 10.1074/jbc.M709852200 · DOI · Paper page
  27. Chiang, 2017, Relationships among cortical glutathione levels, brain amyloidosis, and memory in healthy older adults investigated in vivo with (1)H-MRS and Pittsburgh Compound-B PET, AJNR Am. J. Neuroradiol., 38, 1130, 10.3174/ajnr.A5143 · DOI · Paper page
  28. Chohan, 2006, Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine, FEBS Lett., 580, 3973, 10.1016/j.febslet.2006.06.021 · DOI · Paper page
  29. Cohen, 2004, GSK3 inhibitors: development and therapeutic potential, Nat. Rev. Drug Discov., 3, 479, 10.1038/nrd1415 · DOI · Paper page
  30. Cowan, 2012, What is the pathological significance of tau oligomers?, Biochem. Soc. Trans., 40, 693, 10.1042/BST20120135 · DOI · Paper page
  31. Derry, 2017, Correlating quantitative susceptibility mapping with cognitive decline in Alzheimer’s disease, Brain, 140, 2066, 10.1093/brain/awx167 · DOI
  32. Dickson, 2010, Neuropathology of non-Alzheimer degenerative disorders, Int. J. Clin. Exp. Pathol., 3, 1
  33. Dineley, 2014, Insulin resistance in Alzheimer’s disease, Neurobiol. Dis., 72, 92, 10.1016/j.nbd.2014.09.001 · DOI · Paper page
  34. Dixon, 2012, Ferroptosis: an iron-dependent form of nonapoptotic cell death, Cell, 149, 1060, 10.1016/j.cell.2012.03.042 · DOI · Paper page
  35. Dlouhy, 2019, Fluorescence resonance energy transfer links membrane ferroportin, hephaestin but not ferroportin, amyloid precursor protein complex with iron efflux, J. Biol. Chem., 294, 4202, 10.1074/jbc.RA118.005142 · DOI
  36. Doll, 2017, Iron and ferroptosis: a still ill-defined liaison, IUBMB Life, 69, 423, 10.1002/iub.1616 · DOI · Paper page
  37. Dringen, 2000, Glutathione metabolism in brain: metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species, Eur. J. Biochem., 267, 4912, 10.1046/j.1432-1327.2000.01597.x · DOI · Paper page
  38. Duce, 2010, Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease, Cell, 142, 857, 10.1016/j.cell.2010.08.014 · DOI · Paper page
  39. Egaña, 2003, Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures, BioMetals, 16, 215, 10.1023/A:1020727218493 · DOI
  40. Eto, 2002, Brain hydrogen sulfide is severely decreased in Alzheimer’s disease, Biochem. Biophys. Res. Commun., 293, 1485, 10.1016/S0006-291X(02)00422-9 · DOI · Paper page
  41. Everett, 2014, Evidence of redox-active iron formation following aggregation of ferrihydrite and the Alzheimer’s disease peptide beta-amyloid, Inorg. Chem., 53, 2803, 10.1021/ic402406g · DOI · Paper page
  42. Everett, 2014, Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer’s disease peptide beta-amyloid (1-42), J. R. Soc. Interface, 11, 10.1098/rsif.2014.0165 · DOI · Paper page
  43. Farina, 2017, Vitamin E for Alzheimer’s dementia and mild cognitive impairment, Cochrane Database Syst. Rev., 4, CD002854
  44. Ferrer, 2005, Current advances on different kinases involved in Tau Phosphorylation, and implications in Alzheimer’s disease and tauopathies, Curr. Alzheimer Res., 2, 3, 10.2174/1567205052772713 · DOI · Paper page
  45. Filograna, 2016, Anti-oxidants in Parkinson’s disease therapy: a critical point of view, Curr. Neuropharmacol., 14, 260, 10.2174/1570159X13666151030102718 · DOI · Paper page
  46. Finkelstein, 2017, The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease, Acta Neuropathol. Commun., 5, 53, 10.1186/s40478-017-0456-2 · DOI
  47. Flora, 2010, Chelation in metal intoxication, Int. J. Environ. Res. Public Health, 7, 2745, 10.3390/ijerph7072745 · DOI · Paper page
  48. Fu, 2014, Pharmacophore modeling, ensemble docking, virtual screening, and biological evaluation on glycogen synthase Kinase-3beta, Mol. Inform., 33, 610, 10.1002/minf.201400044 · DOI
  49. Galimberti, 2011, Disease-modifying treatments for Alzheimer’s disease, Ther. Adv. Neurol. Disord., 4, 203, 10.1177/1756285611404470 · DOI · Paper page
  50. Garrick, 2003, DMT1: a mammalian transporter for multiple metals, Biometals, 16, 41, 10.1023/A:1020702213099 · DOI · Paper page
  51. Gaschler, 2018, Determination of the subcellular localization and mechanism of action of ferrostatins in suppressing ferroptosis, ACS Chem. Biol., 13, 1013, 10.1021/acschembio.8b00199 · DOI · Paper page
  52. George, 2011, The evolving classification of dementia: placing the DSM-V in a meaningful historical and cultural context and pondering the future of “Alzheimer’s”, Cult. Med. Psychiatry, 35, 417, 10.1007/s11013-011-9219-x · DOI
  53. Gerson, 2014, Characterization of tau oligomeric seeds in progressive supranuclear palsy, Acta Neuropathol. Commun., 2, 73, 10.1186/2051-5960-2-73 · DOI · Paper page
  54. Ghosh, 2014, Dual-energy precursor and nuclear erythroid-related factor 2 activator treatment additively improve redox glutathione levels and neuron survival in aging and Alzheimer mouse neurons upstream of reactive oxygen species, Neurobiol. Aging, 35, 179, 10.1016/j.neurobiolaging.2013.06.023 · DOI
  55. Gong, 2000, Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain, J. Biol. Chem., 275, 5535, 10.1074/jbc.275.8.5535 · DOI · Paper page
  56. Haile, 1999, Regulation of genes of iron metabolism by the iron-response proteins, Am. J. Med. Sci., 318, 230, 10.1016/S0002-9629(15)40627-5 · DOI
  57. Hallgren, 1958, The effect of non-haemin iron in the human brain, J. Neurochem., 3, 41, 10.1111/j.1471-4159.1958.tb12607.x · DOI · Paper page
  58. Hampel, 2005, Apoptosis resistance of senescent human fibroblasts is correlated with the absence of nuclear IGFBP-3, Aging Cell, 4, 325, 10.1111/j.1474-9726.2005.00180.x · DOI · Paper page
  59. Hare, 2016, Iron and dopamine: a toxic couple, Brain, 139, 1026, 10.1093/brain/aww022 · DOI · Paper page
  60. Hare, 2015, Decreased plasma iron in Alzheimer’s disease is due to transferrin desaturation, ACS Chem. Neurosci., 6, 398, 10.1021/cn5003557 · DOI · Paper page
  61. Harris, 2012, Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits, PLoS One, 7, e45881, 10.1371/journal.pone.0045881 · DOI · Paper page
  62. Hegde, 2009, Challenges associated with metal chelation therapy in Alzheimer’s disease, J. Alzheimers Dis., 17, 457, 10.3233/JAD-2009-1068 · DOI · Paper page
  63. Honarmand Ebrahimi, 2013, The amyloid precursor protein (APP) does not have a ferroxidase site in its E2 domain, PLoS One, 8, e72177, 10.1371/journal.pone.0072177 · DOI
  64. House, 2012, Aluminium, iron and copper in human brain tissues donated to the Medical Research Council’s Cognitive Function and Ageing Study, Metallomics, 4, 56, 10.1039/C1MT00139F · DOI · Paper page
  65. Iqbal, 2010, Alzheimer’s disease, a multifactorial disorder seeking multitherapies, Alzheimers Dement., 6, 420, 10.1016/j.jalz.2010.04.006 · DOI · Paper page
  66. Iqbal, 2013, Hyperphosphorylation-induced tau oligomers, Front. Neurol., 4, 112, 10.3389/fneur.2013.00112 · DOI · Paper page
  67. Jicha, 2009, Is passive immunization for Alzheimer’s disease’ alive and well’ or’ dead and buried’?, Expert Opin. Biol. Ther., 9, 481, 10.1517/14712590902828285 · DOI
  68. Kahklon, 2002, The labile iron pool: characterization, measurement, and participation in cellular processes, Free Radic. Biol. Med., 33, 1037
  69. Kanaan, 2011, Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases, J. Neurosci., 31, 9858, 10.1523/JNEUROSCI.0560-11.2011 · DOI · Paper page
  70. Kepp, 2012, Bioinorganic chemistry of Alzheimer’s disease, Chem. Rev., 112, 5193, 10.1021/cr300009x · DOI · Paper page
  71. Khatoon, 1994, Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains, FEBS Lett., 351, 80, 10.1016/0014-5793(94)00829-9 · DOI · Paper page
  72. Kim, 2015, Identification of disulfide cross-linked tau dimer responsible for tau propagation, Sci. Rep., 5, 15231, 10.1038/srep15231 · DOI · Paper page
  73. Kim, 2016, Six-transmembrane epithelial antigen of prostate 1 (STEAP1) has a single b heme and is capable of reducing metal ion complexes and oxygen, Biochemistry, 55, 6673, 10.1021/acs.biochem.6b00610 · DOI
  74. Kontoghiorghes, 2000, Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1), Transfus. Sci., 23, 211, 10.1016/S0955-3886(00)00089-8 · DOI
  75. Kontsekova, 2014, First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model, Alzheimers Res. Ther., 6, 44, 10.1186/alzrt278 · DOI · Paper page
  76. Köpke, 1993, Microtubule-associated protein tau: abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease, J. Biol. Chem., 268, 24374, 10.1016/S0021-9258(20)80536-5 · DOI · Paper page
  77. Köpke, 1993, Microtubule-associated protein tau: abnormal phosphorylatoin of a non-paired helical filament pool in Alzheimer disease, J. Biol. Chem., 268, 24374, 10.1016/S0021-9258(20)80536-5 · DOI · Paper page
  78. Kristinsson, 2012, Ceruloplasmin and iron in Alzheimer’s disease and Parkinson’s disease: a synopsis of recent studies, Neuropsychiatr. Dis. Treat., 8, 515
  79. Kryscio, 2017, Association of antioxidant supplement use and dementia in the prevention of Alzheimer’s disease by vitamin E and selenium trial (PREADViSE), JAMA Neurol., 74, 567, 10.1001/jamaneurol.2016.5778 · DOI · Paper page
  80. Lambert, 2010, The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention, Arch. Biochem. Biophys., 501, 65, 10.1016/j.abb.2010.06.013 · DOI · Paper page
  81. Lannfelt, 2008, Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial, Lancet Neurol., 7, 779, 10.1016/S1474-4422(08)70167-4 · DOI · Paper page
  82. Larson, 2004, Survival after initial diagnosis of Alzheimer disease, Ann. Intern. Med., 140, 501, 10.7326/0003-4819-140-7-200404060-00008 · DOI · Paper page
  83. Lashuel, 2013, The many faces of alpha-synuclein: from structure and toxicity to therapeutic target, Nat. Rev. Neurosci., 14, 38, 10.1038/nrn3406 · DOI · Paper page
  84. Lei, 2015, Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse, Neurobiol. Dis., 81, 168, 10.1016/j.nbd.2015.03.015 · DOI
  85. Lei, 2014, Motor and cognitive deficits in aged tau knockout mice in two background strains, Mol. Neurodegener., 9, 29, 10.1186/1750-1326-9-29 · DOI · Paper page
  86. Lloret, 2009, Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental, J. Alzheimers Dis., 17, 143, 10.3233/JAD-2009-1033 · DOI · Paper page
  87. Lodish, 2010, Endocrine side effects of broad-acting kinase inhibitors, Endocr. Relat. Cancer, 17, R233, 10.1677/ERC-10-0082 · DOI · Paper page
  88. Lovell, 1995, Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease, Neurology, 45, 1594, 10.1212/WNL.45.8.1594 · DOI · Paper page
  89. Lovell, 2000, Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer’s disease brain, Free Radic. Biol. Med., 28, 418, 10.1016/S0891-5849(99)00258-0 · DOI · Paper page
  90. Maeda, 2007, Granular tau oligomers as intermediates of tau filaments, Biochemistry, 46, 3856, 10.1021/bi061359o · DOI · Paper page
  91. Mandal, 2015, Brain glutathione levels—a novel biomarker for mild cognitive impairment and Alzheimer’s disease, Biol. Psychiatry, 78, 702, 10.1016/j.biopsych.2015.04.005 · DOI · Paper page
  92. Mander, 2017, Correlating quantitative susceptibility mapping with cognitive decline in Alzheimer’s disease, Brain, 140, 2066, 10.1093/brain/awx174 · DOI
  93. Markesbery, 1997, Oxidative stress hypothesis in Alzheimer’s disease, Free Radic. Biol. Med., 23, 134, 10.1016/S0891-5849(96)00629-6 · DOI · Paper page
  94. Martin, 2010, Recent insights into protein phosphatase 2A structure and regulation: the reasons why PP2A is no longer considered as a lazy passive housekeeping enzyme, Biotechnol. Agron. Soc. Environ., 14, 243
  95. Martini, 2007, Hyperglycemia in acute ischemic stroke: a vascular perspective, J. Cereb. Blood Flow Metab., 27, 435, 10.1038/sj.jcbfm.9600355 · DOI · Paper page
  96. Matenia, 2009, The tau of MARK: a polarized view of the cytoskeleton, Trends Biochem. Sci., 34, 332, 10.1016/j.tibs.2009.03.008 · DOI · Paper page
  97. McCaddon, 2003, Alzheimer’s disease and total plasma aminothiols, Biol. Psychiatry, 53, 254, 10.1016/S0006-3223(02)01451-8 · DOI
  98. McKhann, 1984, Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease, Neurology, 2, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
  99. McLachlan, 1991, Intramuscular desferrioxamine in patients with Alzheimer’s disease, Lancet, 337, 1304, 10.1016/0140-6736(91)92978-B · DOI · Paper page
  100. Medina, 2016, New features about tau function and dysfunction, Biomolecules, 6, 10.3390/biom6020021 · DOI · Paper page
  101. Mitra, 2014, Revisiting metal toxicity in neurodegenerative diseases and stroke: therapeutic potential, Neurol. Res. Ther., 1
  102. Mohamed, 2013, Tau-derived-hexapeptide 306VQIVYK311 aggregation inhibitors: nitrocatechol moiety as a pharmacophore in drug design, ACS Chem. Neurosci., 4, 1559, 10.1021/cn400151a · DOI
  103. Moos, 2007, Iron trafficking inside the brain, J. Neurochem., 103, 1730, 10.1111/j.1471-4159.2007.04976.x · DOI · Paper page
  104. Mun, 2010, Identification of CD44 as a senescence-induced cell adhesion gene responsible for the enhanced monocyte recruitment to senescent endothelial cells, Am. J. Physiol. Heart Circ. Physiol., 298, H2102, 10.1152/ajpheart.00835.2009 · DOI · Paper page
  105. Murayama, 1999, Interaction of aluminum with PHFτ in Alzheimer’s disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method, Am. J. Pathol., 155, 877, 10.1016/S0002-9440(10)65187-5 · DOI
  106. Nielsen, 2003, Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases, Br. J. Haematol., 123, 952, 10.1046/j.1365-2141.2003.04708.x · DOI
  107. Novak, 2017, Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial, Lancet Neurol., 16, 123, 10.1016/S1474-4422(16)30331-3 · DOI · Paper page
  108. Nubling, 2012, Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with alpha-synuclein at the single molecule level, Mol. Neurodegener., 7, 35, 10.1186/1750-1326-7-35 · DOI · Paper page
  109. O’Callaghan, 2017, Tissue magnetic susceptibility mapping as a marker of tau pathology in Alzheimer’s disease, Neuroimage, 159, 334, 10.1016/j.neuroimage.2017.08.003 · DOI
  110. Petry, 2014, Specificity of anti-tau antibodies when analyzing mice models of Alzheimer’s disease: problems and solutions, PLoS One, 9, e94251, 10.1371/journal.pone.0094251 · DOI · Paper page
  111. Plascencia-Villa, 2016, High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer’s disease, Sci. Rep., 6, 24873, 10.1038/srep24873 · DOI · Paper page
  112. Porter, 2005, Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use, Ann. N. Y. Acad. Sci., 1054, 155, 10.1196/annals.1345.018 · DOI · Paper page
  113. Pradeepkiran, 2019, Structure based design and molecular docking studies for phosphorylated tau inhibitors in Alzheimer’s disease, Cells, 8, 10.3390/cells8030260 · DOI
  114. Prasanthi, 2012, Deferiprone reduces amyloid-beta and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet, J. Alzheimers Dis., 30, 167, 10.3233/JAD-2012-111346 · DOI · Paper page
  115. Raha, 2013, The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer’s disease, Acta Neuropathol. Commun., 1, 1, 10.1186/2051-5960-1-55 · DOI · Paper page
  116. Ramos, 2014, Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes, J. Trace Elem. Med. Biol., 28, 13, 10.1016/j.jtemb.2013.08.001 · DOI · Paper page
  117. Rane, 2019, An acetylation mimicking mutation, K274Q, in tau imparts neurotoxicity by enhancing tau aggregation and inhibiting tubulin polymerization, Biochem. J., 476, 1401, 10.1042/BCJ20190042 · DOI · Paper page
  118. Rickle, 2004, Akt activity in Alzheimer’s disease and other neurodegenerative disorders, Neurochemistry, 15, 955
  119. Rietjens, 2002, The pro-oxidant chemistry of the natural antioxidants vitamin C, vitamin E, carotenoids and flavonoids, Environ. Toxicol. Pharmacol., 11, 321, 10.1016/S1382-6689(02)00003-0 · DOI · Paper page
  120. Robinson, 2009, Hemin toxicity: a preventable source of brain damage following hemorrhagic stroke, Redox Rep., 14, 228, 10.1179/135100009X12525712409931 · DOI · Paper page
  121. Salgado, 2017, The reactivity and reaction pathway of Fenton reactions driven by substituted 1,2-dihydroxybenzenes, Environ. Sci. Technol., 51, 3687, 10.1021/acs.est.6b05388 · DOI
  122. Samuel, 2014, Hydrophilic carbon clusters as therapeutic, high-capacity antioxidants, Trends Biotechnol., 32, 501, 10.1016/j.tibtech.2014.08.005 · DOI
  123. Sayre, 2000, In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer’s disease: a central role for bound transition metals, J. Neurochem., 74, 270, 10.1046/j.1471-4159.2000.0740270.x · DOI · Paper page
  124. Schrag, 2011, Iron, zinc and copper in the Alzheimer’s disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion, Prog. Neurobiol., 94, 296, 10.1016/j.pneurobio.2011.05.001 · DOI · Paper page
  125. Schuff, 2009, MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers, Brain, 132, 1067, 10.1093/brain/awp007 · DOI · Paper page
  126. Sharma, 2018, Advances in multi-functional ligands and the need for metal-related pharmacology for the management of Alzheimer disease, Front. Pharmacol., 9, 1247, 10.3389/fphar.2018.01247 · DOI · Paper page
  127. Shin, 2003, A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated τ of Alzheimer’s disease, Brain Res., 961, 139, 10.1016/S0006-8993(02)03893-3 · DOI
  128. Shin, 1994, Aluminum modifies the properties of Alzheimer’s disease PHFT proteins in vivo and in vitro, J. Neurosci., 14, 7221, 10.1523/JNEUROSCI.14-11-07221.1994 · DOI
  129. Smith, 1997, Iron accumulation in Alzheimer disease is a source of redox-generated free radicals, Proc. Natl. Acad. Sci. U. S. A., 94, 9866, 10.1073/pnas.94.18.9866 · DOI · Paper page
  130. Soeda, 2015, Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups, Nat. Commun., 6, 10216, 10.1038/ncomms10216 · DOI · Paper page
  131. Stamer, 2002, Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress, J. Cell Biol., 156, 1051, 10.1083/jcb.200108057 · DOI · Paper page
  132. Stankowski, 2012, Ironing out tau’s role in Parkinsonism, Nat. Med., 18, 197, 10.1038/nm.2668 · DOI
  133. Stoothoff, 2005, Tau phosphorylation: physiological and pathological consequences, Biochim. Biophys. Acta, 1739, 280, 10.1016/j.bbadis.2004.06.017 · DOI · Paper page
  134. Tariot, 2004, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil, JAMA, 291, 317, 10.1001/jama.291.3.317 · DOI · Paper page
  135. Telling, 2017, Iron biochemistry is correlated with amyloid plaque morphology in an established mouse model of Alzheimer’s disease, Cell Chem. Biol., 24, 10.1016/j.chembiol.2017.07.014 · DOI · Paper page
  136. Uranga, 2009, Iron-induced oxidative injury differentially regulates PI3K/Akt/GSK3beta pathway in synaptic endings from adult and aged rats, Toxicol. Sci., 111, 331, 10.1093/toxsci/kfp152 · DOI
  137. van Bergen, 2016, Colocalization of cerebral iron with amyloid beta in mild cognitive impairment, Sci. Rep., 6, 35514, 10.1038/srep35514 · DOI · Paper page
  138. Veinbergs, 2000, Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice, Eur. J. Neurosci., 12, 4541
  139. Vossel, 2010, Tau reduction prevents Ab-induced defects in axonal transport, Science, 330, 198, 10.1126/science.1194653 · DOI · Paper page
  140. Wallin, 2018, The neuronal tau protein blocks in vitro fibrillation of the amyloid-beta (Abeta) peptide at the oligomeric stage, J. Am. Chem. Soc., 140, 8138, 10.1021/jacs.7b13623 · DOI
  141. Wang, 2012, Iron enhances the neurotoxicity of amyloid beta, Transl. Stroke Res., 3, 107, 10.1007/s12975-011-0099-8 · DOI
  142. Wang, 2010, Structural basis for certain naturally occurring bioflavonoids to function as reducing co-substrates of cyclooxygenase I and II, PLoS One, 5, e12316, 10.1371/journal.pone.0012316 · DOI
  143. Wang, 2017, Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: is damage response signaling a potential therapeutic target?, Mech. Ageing Dev., 161, 163, 10.1016/j.mad.2016.09.005 · DOI
  144. Wang, 2017, Tau interactome mapping based identification of Otub1 as tau deubiquitinase involved in accumulation of pathological tau forms in vitro and in vivo, Acta Neuropathol., 133, 731, 10.1007/s00401-016-1663-9 · DOI · Paper page
  145. Ward, 2014, The role of iron in brain ageing and neurodegenerative disorders, Lancet Neurol., 13, 1045, 10.1016/S1474-4422(14)70117-6 · DOI · Paper page
  146. Ward, 2012, Tau oligomers and tau toxicity in neurodegenerative disease, Biochem. Soc. Trans., 40, 667, 10.1042/BST20120134 · DOI · Paper page
  147. Waxman, 2011, Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau, J. Neurosci., 31, 7604, 10.1523/JNEUROSCI.0297-11.2011 · DOI · Paper page
  148. Webb, 1973, Spectroscopic and magnetic studies of iron(111) phosvitins, Biochemistry, 12
  149. Weinreb, 2009, Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties, Genes Nutr., 4, 283, 10.1007/s12263-009-0143-4 · DOI · Paper page
  150. Weinshenker, 2018, Long road to ruin: noradrenergic dysfunction in neurodegenerative disease, Trends Neurosci., 41, 211, 10.1016/j.tins.2018.01.010 · DOI · Paper page
  151. West, 2017, Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies, J. Prev. Alzheimers Dis., 4, 236
  152. Wilkinson, 2004, Protein disulfide isomerase, Biochim. Biophys. Acta, 1699, 35, 10.1016/S1570-9639(04)00063-9 · doi:10.1016/s1570-9639(04)00063-9 · Paper page
  153. Wischik, 2014, Tau-aggregation inhibitor therapy for Alzheimer’s disease, Biochem. Pharmacol., 88, 529, 10.1016/j.bcp.2013.12.008 · DOI · Paper page
  154. Wong, 1997, Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig, Biometals, 10, 247, 10.1023/A:1018312113969 · doi:10.1023/a:1018312113969
  155. Wong, 2014, Beta-amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin, PLoS One, 9, e114174, 10.1371/journal.pone.0114174 · DOI · Paper page
  156. Yang, 2007, Deferasirox: a review of its use in the management of transfusional chronic iron overload, Drugs, 67, 2211, 10.2165/00003495-200767150-00007 · DOI
  157. Yoo, 2010, Delineating the role of glutathione peroxidase 4 in protecting cells against lipid hydroperoxide damage and in Alzheimer’s disease, Antioxid. Redox Signal., 12, 819, 10.1089/ars.2009.2891 · DOI · Paper page
  158. Yuzwa, 2012, Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation, Nat. Chem. Biol., 8, 393, 10.1038/nchembio.797 · DOI · Paper page
  159. Zecca, 2001, Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour, Mol. Pathol., 54, 414
  160. Zhang, 2010, Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner, Brain Res., 1345, 176, 10.1016/j.brainres.2010.04.074 · DOI
  161. Zhang, 2014, Synthesis of hierarchical iron hydrogen phosphate crystal as a robust peroxidase mimic for stable H(2)O(2) detection, ACS Appl. Mater. Interfaces, 6, 14433, 10.1021/am503708a · DOI
  162. Zhang, 2018, Alpha-lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice, Redox Biol., 14, 535, 10.1016/j.redox.2017.11.001 · DOI · Paper page
  163. Zhang, 2017, Selenomethionine mitigates cognitive decline by targeting both tau hyperphosphorylation and autophagic clearance in an Alzheimer’s disease mouse model, J. Neurosci., 37, 2449, 10.1523/JNEUROSCI.3229-16.2017 · DOI · Paper page
  164. Zilka, 2017, On the mechanism of cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death, ACS Cent. Sci., 3, 232, 10.1021/acscentsci.7b00028 · DOI · Paper page

Cited by

See all 140

Metadata

Authors
Derry, P. J., Hegde, M. L., Jackson, G. R., Kayed, R., Tour, J. M., Tsai, A.-L., & Kent, T. A.
Venue
Progress in Neurobiology
Publisher
Elsevier BV
Published
2020-01
Volume
184
Pages
101716
ISSN
0301-0082 (ISSN-L)
OpenAlex
W2980072878
Cited by
140
References
90
FWCI
10.00
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Welch Foundation
  • National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective. https://app.cochat.ai/papers/10.1016/j.pneurobio.2019.101716
The paper
Derry, P. J., Hegde, M. L., Jackson, G. R., Kayed, R., Tour, J. M., Tsai, A.-L., & Kent, T. A. (2020). Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2019.101716

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.